722
Participants
Start Date
January 29, 2002
Primary Completion Date
November 30, 2006
Study Completion Date
May 31, 2009
bevacizumab
10 mg/kg following paclitaxel treatment on weeks 1 and 3 of every 4-week cycle
Paclitaxel
90 mg/m2 IV infusion over 1 hour every week for 3 weeks followed by 1 week rest
CCOP - Upstate Carolina, Spartanburg
Mayo Clinic - Jacksonville, Jacksonville
MBCCOP - Gulf Coast, Mobile
CCOP - Dayton, Dayton
CCOP - Michigan Cancer Research Consortium, Ann Arbor
CCOP - St. Vincent Hospital Cancer Center, Green Bay, Green Bay
CCOP - Metro-Minnesota, Saint Louis Park
CCOP - Duluth, Duluth
Mayo Clinic Cancer Center, Rochester
CentraCare Health Plaza, Saint Cloud
CCOP - Sioux Community Cancer Consortium, Sioux Falls
Rapid City Regional Hospital, Rapid City
CCOP - Merit Care Hospital, Fargo
Altru Cancer Center, Grand Forks
CCOP - Illinois Oncology Research Association, Peoria
CCOP - Carle Cancer Center, Urbana
CCOP - Missouri Valley Cancer Consortium, Omaha
CCOP - Ochsner, New Orleans
CCOP - Oklahoma, Tulsa
CCOP - Mayo Clinic Scottsdale Oncology Program, Scottsdale
CCOP - Atlanta Regional, Atlanta
CCOP - Cedar Rapids Oncology Project, Cedar Rapids
CCOP - Iowa Oncology Research Association, Des Moines
Siouxland Hematology-Oncology, Sioux City
Medcenter One Health System, Bismarck
CCOP - Toledo Community Hospital, Toledo
CCOP - Geisinger Clinic and Medical Center, Danville
Allegheny General Hospital, Pittsburgh
British Columbia Cancer Agency, Vancouver
Allan Blair Cancer Centre, Regina
Collaborators (1)
National Cancer Institute (NCI)
NIH
North Central Cancer Treatment Group
NETWORK
NCIC Clinical Trials Group
NETWORK
NSABP Foundation Inc
NETWORK
Eastern Cooperative Oncology Group
NETWORK